A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“also debated are specific benefits of eicosapentaenoic acid (EPA)”
From Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis (2024) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness
Vlachopoulos, C., Aznaouridis, K., & Stefanadis, C. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.061 · Cited by 4,165
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citationPro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552
Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428
Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace
Förstermann, U., & Münzel, T. (2006) · Circulation · doi:10.1161/circulationaha.105.602532 · Cited by 1,957
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Landmesser, U., Dikalov, S., Price, S. R., McCann, L., Fukai, T., Holland, S. M., Mitch, W. E., & Harrison, D. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200314172 · Cited by 1,660
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811403 · Cited by 979
Dyall, S. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00052 · Cited by 943
New Markers of Inflammation and Endothelial Cell Activation: Part I
Szmitko, P. E., Wang, C.-H., Weisel, R. D., de Almeida, J. R., Anderson, T. J., & Verma, S. (2003) · Circulation · doi:10.1161/01.cir.0000089190.95415.9f · Cited by 738
Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Duplain, H., Burcelin, R., Sartori, C., Cook, S., Egli, M., Lepori, M., Vollenweider, P., Pedrazzini, T., Nicod, P., Thorens, B., et al. (2001) · Circulation · doi:10.1161/01.cir.104.3.342 · Cited by 533
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407
Self-citationPradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Self-citationEffects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction
Kalstad, A. A., Myhre, P. L., Laake, K., Tveit, S. H., Schmidt, E. B., Smith, P., Nilsen, D. W. T., Tveit, A., Fagerland, M. W., Solheim, S., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052209 · Cited by 311
Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA
Albert, B. B., Derraik, J. G. B., Cameron-Smith, D., Hofman, P. L., Tumanov, S., Villas-Boas, S. G., Garg, M. L., & Cutfield, W. S. (2015) · Scientific Reports · doi:10.1038/srep07928 · Cited by 238
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195
Self-citationElam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Mason, R. P., Jacob, R. F., Shrivastava, S., Sherratt, S. C. R., & Chattopadhyay, A. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.10.002 · Cited by 179
Self-citationShaikh, S. R., Kinnun, J. J., Leng, X., Williams, J. A., & Wassall, S. R. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.04.020 · Cited by 179
Borow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175
Docosahexaenoic and eicosapentaenoic acids segregate differently between raft and nonraft domains
Williams, J. A., Batten, S. E., Harris, M., Rockett, B. D., Shaikh, S. R., Stillwell, W., & Wassall, S. R. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.06.016 · Cited by 168
Molecular organization of cholesterol in polyunsaturated membranes: microdomain formation
Brzustowicz, M. R., Cherezov, V., Caffrey, M., Stillwell, W., & Wassall, S. R. (2002) · Biophysical Journal · doi:10.1016/s0006-3495(02)75394-0 · Cited by 161
Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-012-0002-3 · Cited by 141
Shaikh, S. R. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.07.001 · Cited by 134
Nishio, R., Shinke, T., Otake, H., Nakagawa, M., Nagoshi, R., Inoue, T., Kozuki, A., Hariki, H., Osue, T., Taniguchi, Y., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.025 · Cited by 133
Preston Mason, R. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0762-1 · Cited by 129
Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
Cockbain, A. J., Volpato, M., Race, A. D., Munarini, A., Fazio, C., Belluzzi, A., Loadman, P. M., Toogood, G. J., & Hull, M. A. (2014) · Gut · doi:10.1136/gutjnl-2013-306445 · Cited by 115
Yamada, H., Yoshida, M., Nakano, Y., Suganami, T., Satoh, N., Mita, T., Azuma, K., Itoh, M., Yamamoto, Y., Kamei, Y., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.171736 · Cited by 112
Kučerka, N., Marquardt, D., Harroun, T. A., Nieh, M.-P., Wassall, S. R., de Jong, D. H., Schäfer, L. V., Marrink, S. J., & Katsaras, J. (2010) · Biochemistry · doi:10.1021/bi100891z · Cited by 112
Mason, R. P., & Sherratt, S. C. R. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.127 · Cited by 108
Self-citationMineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa117 · Cited by 103
Self-citationBhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Jiao, L., Tardif, J.-C., Gregson, J., Pocock, S. J., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.043 · Cited by 97
Self-citationSherratt, S. C. R., & Mason, R. P. (2018) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2018.01.002 · Cited by 95
Self-citationEPA and DHA containing phospholipids have contrasting effects on membrane structure
Sherratt, S. C. R., Juliano, R. A., Copland, C., Bhatt, D. L., Libby, P., & Mason, R. P. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100106 · Cited by 92
Self-citationTriglycerides on the rise: should we swap seats on the seesaw?
Libby, P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu500 · Cited by 85
Self-citationMason, R. P., Sherratt, S. C. R., & Jacob, R. F. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000379 · Cited by 72
Self-citationGaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.035 · Cited by 61
Self-citationKučerka, N., Marquardt, D., Harroun, T. A., Nieh, M.-P., Wassall, S. R., & Katsaras, J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907659u · Cited by 54
Lakshmanan, S., Shekar, C., Kinninger, A., Dahal, S., Onuegbu, A., Cai, A. N., Hamal, S., Birudaraju, D., Roy, S. K., Nelson, J. R., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz329 · Cited by 42
Self-citationAre dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence
Sherratt, S. C. R., Lero, M., & Mason, R. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000665 · Cited by 33
Self-citation
Research works printed but not linked: 133
- Bhatt, 2020, A Revolution in Omega-3 Fatty Acid Research∗, Journal of the American College of Cardiology, 76, 2098, 10.1016/j.jacc.2020.09.005 · DOI
- Mason, 2022, Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction, Metabolism - Clinical and Experimental, 130
- Budoff, 2020, Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial, European Heart Journal, 41, 3925, 10.1093/eurheartj/ehaa652 · DOI · Paper page
- Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, The Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 · DOI · Paper page
- Watanabe, 2017, A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins, Journal of Cardiology, 70, 537, 10.1016/j.jjcc.2017.07.007 · DOI · Paper page
- Alfaddagh, 2017, Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial, J Am Heart Assoc, 6, 10.1161/JAHA.117.006981 · DOI · Paper page
- Nicholls, 2020, Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial, JAMA, 324, 2268, 10.1001/jama.2020.22258 · DOI · Paper page
- Bhatt, 2019, Cardiovascular risk reduction with icosapent ethyl. Reply, N Engl J Med, 380, 1678, 10.1056/NEJMoa1812792 · DOI · Paper page
- Pisaniello, 2020, Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events, European Medical Journal, 5, 29
- Aung, 2018, Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals, JAMA Cardiology, 3, 225, 10.1001/jamacardio.2017.5205 · DOI · Paper page
- Mason, 2021, Is there a role for omega-3 fatty acids in cardiovascular disease risk reduction?, eClinicalMedicine, 39
- Davidson, 2014, Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST), Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 1298, 10.1161/ATVBAHA.113.302926 · DOI · Paper page
- 2022, Kowa Research Institute I. Kowa to discontine K-877 (pemafibrate) "PROMINENT" cardiovascular outcomes study, Cision PR Newswire
- Kita, 2020, Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study, Journal of the American Heart Association, 9, 10.1161/JAHA.119.015593 · DOI · Paper page
- Motoyama, 2021, Effect of Omega-3 Fatty Acids on Coronary Plaque Morphology - A Serial Computed Tomography Angiography Study, Circ J
- Nakajima, 2011, Orally Administered Eicosapentaenoic Acid Induces Rapid Regression of Atherosclerosis Via Modulating the Phenotype of Dendritic Cells in LDL Receptor-Deficient Mice, Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 1963, 10.1161/ATVBAHA.111.229443 · DOI · Paper page
- Sato, 2019, Preferential incorporation of administered eicosapentaenoic acid into thin-cap atherosclerotic plaques, Arterioscler Thromb Vasc Biol, 39, 1802, 10.1161/ATVBAHA.119.313093 · DOI
- Williams, 2020, Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction, Circulation, 141, 1452, 10.1161/CIRCULATIONAHA.119.044720 · DOI · Paper page
- Cawood, 2010, Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability, Atherosclerosis, 212, 252, 10.1016/j.atherosclerosis.2010.05.022 · DOI · Paper page
- Sawazaki, 1989, Comparison of the increment in plasma eicosapentaenoate concentrations by fish oil intake between young and middle-aged volunteers, J Nutr Sci Vitaminol (Tokyo), 35, 349, 10.3177/jnsv.35.349 · doi:10.3177/jnsv.35.349
- Subbaiah, 1993, Incorporation of dietary n-3 fatty acids into molecular species of phosphatidyl choline and cholesteryl ester in normal human plasma, American Journal of Clinical Nutrition, 58, 360, 10.1093/ajcn/58.3.360 · DOI
- Jacobs, 2021, EPA and DHA differentially modulate membrane elasticity in the presence of cholesterol, Biophysical Journal, 120, 2317, 10.1016/j.bpj.2021.04.009 · DOI · Paper page
- Soni, 2008, Docosahexaenoic acid enhances segregation of lipids between: 2H-NMR study, Biophys J, 95, 203, 10.1529/biophysj.107.123612 · DOI · Paper page
- Querques, 2011, Retina and omega-3, J Nutr Metab, 2011, 10.1155/2011/748361 · DOI
- Innis, 2007, Dietary (n-3) fatty acids and brain development, J Nutr, 137, 855, 10.1093/jn/137.4.855 · DOI · Paper page
- Uauy, 2006, Nutrition in brain development and aging: role of essential fatty acids, Nutr Rev, 64, 10.1301/nr.2006.may.S24-S33 · DOI · Paper page
- Chang, 1995, Attenuation of channel kinetics and conductance by cholesterol: an interpretation using structural stress as a unifying concept, J Membr Biol, 143, 51, 10.1007/BF00232523 · DOI
- Heijman, 2014, Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression, Circulation Research, 114, 1483, 10.1161/CIRCRESAHA.114.302226 · DOI · Paper page
- Maixent, 2002, Remodeling of Na,K-ATPase, and membrane fluidity after atrial fibrillation in sheep, J Recept Signal Transduct Res, 22, 201, 10.1081/RRS-120014596 · DOI
- Doi, 2014, Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study, Int J Cardiol, 176, 577, 10.1016/j.ijcard.2014.08.055 · DOI
- Myhre, 2021, Changes in EPA and DHA during supplementation with omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial, European Heart Journal, 42
- Witztum, 1994, The oxidation hypothesis of atherosclerosis, Lancet, 344, 793, 10.1016/S0140-6736(94)92346-9 · DOI · Paper page
- Chisolm, 2000, The oxidative modification hypothesis of atherogenesis: an overview, Free Radic Biol Med, 28, 1815, 10.1016/S0891-5849(00)00344-0 · DOI · Paper page
- Ehara, 2001, Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes, Circulation, 103, 1955, 10.1161/01.CIR.103.15.1955 · DOI · Paper page
- Walter, 2008, Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study, J Am Coll Cardiol, 51, 1196, 10.1016/j.jacc.2007.11.051 · DOI
- Walter, 2004, Serum levels of TBARS predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study, J Am Coll Cardiol, 44, 1996, 10.1016/j.jacc.2004.08.029 · DOI · Paper page
- Holvoet, 2004, The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort, Diabetes, 53, 1068, 10.2337/diabetes.53.4.1068 · DOI · Paper page
- Mason, 1997, Effect of oxidative stress on membrane structure: Small angle x-ray diffraction analysis, Free Radic Biol Med, 23, 419, 10.1016/S0891-5849(97)00101-9 · DOI
- Mason, 2006, Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism, J Biol Chem, 281, 9337, 10.1074/jbc.M513000200 · DOI · Paper page
- Self-Medlin, 2009, Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation, Biochim Biophys Acta, 1788, 1398, 10.1016/j.bbamem.2009.04.004 · DOI · Paper page
- Wratten, 1992, Structural and dynamic effects of oxidatively modified phospholipids in unsaturated lipid membranes, Biochemistry, 31, 10901, 10.1021/bi00159a034 · doi:10.1021/bi00159a034
- Sherratt, 2020, Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro, Biochimica et Biophysica Acta - Biomembranes, 1862
- Mason, 2015, Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism, Biochimica et Biophysica Acta, 1848
- Jacob, 2013, Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein, J Cardiovasc Pharmacol, 62, 160, 10.1097/FJC.0b013e318294998d · DOI
- Aviram, 1998, Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation, Atherosclerosis, 138, 271, 10.1016/S0021-9150(98)00032-X · DOI · Paper page
- Mason, 2003, Membrane microdomains and vascular biology: emerging role in atherogenesis, Circulation, 107, 2270, 10.1161/01.CIR.0000062607.02451.B6 · DOI · Paper page
- Kellner-Weibel, 1999, Crystallization of free cholesterol in model macrophage foam cells, Arterioscler Thromb Vasc Biol, 19, 1891, 10.1161/01.ATV.19.8.1891 · DOI · Paper page
- Duewell, 2010, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, Nature, 464, 1357, 10.1038/nature08938 · DOI · Paper page
- Amiya, 2013, Angiotensin II impairs endothelial nitric-oxide synthase bioavailability under free cholesterol-enriched conditions via intracellular free cholesterol-rich membrane microdomains, J Biol Chem, 288, 14497, 10.1074/jbc.M112.448522 · DOI
- Abela, 2006, Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events—a novel insight into plaque rupture by scanning electron microscopy, Scanning, 28, 1, 10.1002/sca.4950280101 · DOI
- Phillips, 2001, 7-Ketocholesterol forms crystalline domains in model membranes and murine aortic smooth muscle cells, Atherosclerosis, 159, 125, 10.1016/S0021-9150(01)00504-4 · DOI
- Abela, 2005, Cholesterol crystals cause mechanical damage to biological membranes: a proposed mechanism of plaque rupture and erosion leading to arterial thrombosis, Clin Cardiol, 28, 413, 10.1002/clc.4960280906 · DOI
- Small DM. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis: An Official Journal of the American Heart Association, Inc. 1988;8:103-29. · DOI · Paper page
- Jakus, 2004, Advanced glycation end-products and the progress of diabetic vascular complications, Physiol Res, 53, 131, 10.33549/physiolres.930430 · DOI · Paper page
- Pennathur, 2007, Mechanisms for oxidative stress in diabetic cardiovascular disease, Antioxid Redox Signal, 9, 955, 10.1089/ars.2007.1595 · DOI · Paper page
- Pinel, 2016, EPA prevents fat mass expansion and metabolic disturbances in mice fed with a Western diet [S], Journal of Lipid Research, 57, 1382, 10.1194/jlr.M065458 · DOI
- Al Rijjal, 2021, Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function. iScience, 24
- Pal, 2020, Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner, The FASEB Journal, 34, 10640, 10.1096/fj.202000830R · DOI
- Bhatt, 2022, Icosapent ethyl reduces cardiovascular risk substantially and consistently regardless of waist circumference, Journal of the American College of Cardiology, 79, 1556, 10.1016/S0735-1097(22)02547-5 · doi:10.1016/s0735-1097(22)02547-5
- Tulenko, 1998, Physical effects of cholesterol on arterial smooth muscle membranes: Evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis, J Lipid Res, 39, 947, 10.1016/S0022-2275(20)33861-X · DOI · Paper page
- Paragh, 1999, Altered signal pathway in granulocytes from patients with hypercholesterolemia, Journal of Lipid Research, 40, 1728, 10.1016/S0022-2275(20)33420-9 · doi:10.1016/s0022-2275(20)33420-9
- Fang, 2006, Hypercholesterolemia Suppresses Inwardly Rectifying K+Channels in Aortic Endothelium In Vitro and In Vivo, Circulation Research, 98, 1064, 10.1161/01.RES.0000218776.87842.43 · DOI · Paper page
- Ruocco, 1984, Interaction of cholesterol with galactocerebroside and galactocerebroside-phosphatidylcholine bilayer membranes, Biophys J, 46, 695, 10.1016/S0006-3495(84)84068-0 · DOI
- Mason, 1992, Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer, Mol Pharmacol, 41, 315, 10.1016/S0026-895X(25)08879-0 · DOI · Paper page
- Stary, 1995, A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis, Circulation, 92, 1355, 10.1161/01.CIR.92.5.1355 · DOI · Paper page
- Falk, 2006, Pathogenesis of Atherosclerosis, Journal of the American College of Cardiology, 47, C7, 10.1016/j.jacc.2005.09.068 · DOI · Paper page
- Virmani, 2000, Lessons From Sudden Coronary Death, Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1262, 10.1161/01.ATV.20.5.1262 · DOI · Paper page
- Erdmann, 2013, Dysfunctional nitric oxide signalling increases risk of myocardial infarction, Nature, 504, 432, 10.1038/nature12722 · DOI · Paper page
- Emdin, 2018, Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling, Circulation, 137, 222, 10.1161/CIRCULATIONAHA.117.028021 · DOI · Paper page
- De Caterina, 1994, The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells, Arterioscler Thromb, 14, 1829, 10.1161/01.ATV.14.11.1829 · DOI · Paper page
- Weber, 1995, Docosahexaenoic acid selectively attenuates induction of vascular cell adhesion molecule-1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by tumor necrosis factor-alpha, Arterioscler Thromb Vasc Biol, 15, 622, 10.1161/01.ATV.15.5.622 · DOI · Paper page
- Haiden, 2012, Effect of eicosapentaenoic acid on regional arterial stiffness: Assessment by tissue Doppler imaging, World J Cardiol, 4, 256, 10.4330/wjc.v4.i8.256 · DOI
- Ito, 2014, An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia, J Atheroscler Thromb, 21, 248, 10.5551/jat.19976 · DOI
- Takaki, 2011, Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study, J Atheroscler Thromb, 18, 857, 10.5551/jat.7260 · DOI · Paper page
- Mita, 2007, Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes, Atherosclerosis, 191, 162, 10.1016/j.atherosclerosis.2006.03.005 · DOI
- Li, 2007, Eicosapentaenoic acid modifies lipid composition in caveolae and induces translocation of endothelial nitric oxide synthase, Biochimie, 89, 169, 10.1016/j.biochi.2006.10.009 · DOI
- Mason, 2018, Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin, Biomedicine & Pharmacotherapy, 103, 1231, 10.1016/j.biopha.2018.04.118 · DOI · Paper page
- Hou, 2016, Omega-3 fatty acids, lipid rafts, and T cell signaling, Eur J Pharmacol, 785, 2, 10.1016/j.ejphar.2015.03.091 · DOI · Paper page
- Lee, 2015, Effects of eicosapentaenoic acid on the cytoprotection through Nrf2-mediated heme oxygenase-1 in human endothelial cells, Journal of Cardiovascular Pharmacology, 66, 108, 10.1097/FJC.0000000000000251 · DOI
- Zhang, 2017, Quantitative proteomics reveals key proteins regulated by eicosapentaenoic acid in endothelial activation, Biochemical and Biophysical Research Communications, 487, 464, 10.1016/j.bbrc.2017.04.091 · DOI
- Fredenburgh, 2015, Haeme oxygenase signalling pathway: implications for cardiovascular disease, European Heart Journal, 36, 1512, 10.1093/eurheartj/ehv114 · DOI
- Duckers, 2001, Heme oxygenase-1 protects against vascular constriction and proliferation, Nature Medicine, 7, 693, 10.1038/89068 · DOI · Paper page
- Otterbein, 2003, Heme oxygenase-1: unleashing the protective properties of heme, Trends in Immunology, 24, 449, 10.1016/S1471-4906(03)00181-9 · DOI · Paper page
- Luo, 2018, Heme oxygenase-1 ameliorates oxidative stress-induced endothelial senescence via regulating endothelial nitric oxide synthase activation and coupling, Aging (Albany NY), 10, 1722, 10.18632/aging.101506 · DOI
- Polte, 2000, Heme Oxygenase-1 Is a cGMP-Inducible Endothelial Protein and Mediates the Cytoprotective Action of Nitric Oxide, Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1209, 10.1161/01.ATV.20.5.1209 · DOI · Paper page
- Choi, 2003, Nitric oxide priming protects nitric oxide-mediated apoptosis via heme oxygenase-1 induction, Free Radic Biol Med, 34, 1136, 10.1016/S0891-5849(03)00064-9 · DOI
- Soares, 2004, Heme Oxygenase-1 Modulates the Expression of Adhesion Molecules Associated with Endothelial Cell Activation, The Journal of Immunology, 172, 3553, 10.4049/jimmunol.172.6.3553 · DOI · Paper page
- Ishikawa, 2001, Heme Oxygenase-1 Inhibits Atherosclerotic Lesion Formation in LDL-Receptor Knockout Mice, Circulation Research, 88, 506, 10.1161/01.RES.88.5.506 · DOI · Paper page
- Ignarro, 1987, Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide, Proc Natl Acad Sci USA., 84, 9265, 10.1073/pnas.84.24.9265 · DOI · Paper page
- Ignarro, 2002, Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide, Circ Res, 90, 21, 10.1161/hh0102.102330 · DOI · Paper page
- Anderson, 1995, The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion, N Engl J Med, 332, 488, 10.1056/NEJM199502233320802 · DOI · Paper page
- Mason, 2005, Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans, Circulation, 112, 3795, 10.1161/CIRCULATIONAHA.105.556233 · DOI · Paper page
- Paniagua, 2001, Role of endothelial nitric oxide in shear stress-induced vasodilation of human microvasculature: diminished activity in hypertensive and hypercholesterolemic patients, Circulation, 103, 1752, 10.1161/01.CIR.103.13.1752 · DOI · Paper page
- Nishizaki, 2014, Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome, Am J Cardiol, 113, 441, 10.1016/j.amjcard.2013.10.011 · DOI
- Panza, 1990, Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension, N Engl J Med, 323, 22, 10.1056/NEJM199007053230105 · DOI · Paper page
- Huk, 1997, L-Arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle, Circulation, 96, 667, 10.1161/01.CIR.96.2.667 · DOI · Paper page
- Dawoud, 2018, A nanomedical approach to understanding the mechanism of endothelial function and dysfunction – clinical implications, J Nanomed, 2, 1006
- Malinski, 2005, Understanding nitric oxide physiology in the heart: a nanomedical approach, Am J Cardiol, 96, 10.1016/j.amjcard.2005.07.029 · DOI
- Sherratt, 2021, Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability, Prostaglandins Leukot Essent Fatty Acids, 173
- Drouin, 2019, The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family, Biochimie, 159, 36, 10.1016/j.biochi.2019.01.022 · DOI · Paper page
- Dakroub, 2021, Eicosapentaenoic acid membrane incorporation stimulates ABCA1-mediated cholesterol efflux from human THP-1 macrophages, Biochim Biophys Acta Mol Cell Biol Lipids, 1866
- Singh, 2022, Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT, Journal of the American College of Cardiology, 79, 220, 10.1016/j.jacc.2021.11.005 · DOI
- O'Connell, 2020, Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites, Eur Heart J Suppl, 22
- Shearer, 2009, Impact of circulating esterified eicosanoids and other oxylipins on endothelial function, Current Atherosclerosis Reports, 11, 403, 10.1007/s11883-009-0061-3 · DOI
- Bonafini, 2017, Omega-3 fatty acids and cytochrome P450-derived eicosanoids in cardiovascular diseases: Which actions and interactions modulate hemodynamics?, Prostaglandins & Other Lipid Mediators, 34, 10.1016/j.prostaglandins.2017.01.004 · DOI
- Hansen, 2019, The protectin family of specialized pro-resolving mediators: potent immunoresolvents enabling innovative approaches to target obesity and diabetes, Frontiers in Pharmacology, 9, 10.3389/fphar.2018.01582 · DOI
- Mitchell, 2019, Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system, Br J Pharmacol, 176, 1038, 10.1111/bph.14167 · DOI · Paper page
- Braeckman, 2013, Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study), Prostaglandins, Leukotrienes, and Essential Fatty Acids, 89, 195, 10.1016/j.plefa.2013.07.005 · DOI
- Larsson, 2004, Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms, Am J Clin Nutr, 79, 935, 10.1093/ajcn/79.6.935 · DOI · Paper page
- Gabbs, 2015, Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs, Advances in Nutrition, 6, 513, 10.3945/an.114.007732 · DOI · Paper page
- Djuricic, 2021, Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021, Nutrients, 13, 2421, 10.3390/nu13072421 · DOI · Paper page
- Fredman, 2017, Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy, Am J Pathol, 187, 1211, 10.1016/j.ajpath.2017.01.018 · DOI · Paper page
- Yamada, 2017, Eicosapentaenoic acid shows anti-inflammatory effect via GPR120 in 3T3-L1 adipocytes and attenuates adipose tissue inflammation in diet-induced obese mice, Nutr Metab, 14, 33, 10.1186/s12986-017-0188-0 · DOI
- Chiurchiù, 2019, Resolution of inflammation is altered in chronic heart failure and entails a dysfunctional responsiveness of T lymphocytes, The FASEB Journal, 33, 909, 10.1096/fj.201801017R · DOI
- Zhang, 2005, Dietary (n-3) polyunsaturated fatty acids modulate murine Th1/Th2 balance toward the Th2 pole by suppression of Th1 development, J Nutr, 135, 1745, 10.1093/jn/135.7.1745 · DOI
- Monk, 2012, Dietary n-3 polyunsaturated fatty acids (PUFA) decrease obesity-associated Th17 cell-mediated inflammation during colitis, PLoS One, 7, e49739, 10.1371/journal.pone.0049739 · DOI · Paper page
- Monk, 2013, n3 PUFAs reduce mouse CD4+ T-cell ex vivo polarization into Th17 cells, J Nutr, 143, 1501, 10.3945/jn.113.178178 · DOI
- Chiurchiu, 2016, Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses, Sci Transl Med, 8, 10.1126/scitranslmed.aaf7483 · DOI · Paper page
- Oner, 2021, Resolvin E1 Regulates Th17 Function and T Cell Activation, Frontiers in Immunology, 12
- Nosaka, 2017, Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study, International Journal of Cardiology, 228, 173, 10.1016/j.ijcard.2016.11.105 · DOI · Paper page
- Verma, 2021, Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG, Circulation, 144, 1845, 10.1161/CIRCULATIONAHA.121.056290 · DOI · Paper page
- Peterson, 2022, Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention- insights from REDUCE-IT PCI, Journal of the American Heart Association, 11, 10.1161/JAHA.121.022937 · DOI · Paper page
- 2022, Coronavirus (COVID-19) Dashboard, World Health Organization
- Varga, 2020, Endothelial cell infection and endotheliitis in COVID-19, The Lancet, 1
- Ambrosy, 2021, Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE), Am Heart J, 235, 54, 10.1016/j.ahj.2021.01.018 · DOI
- Mason, 2021, Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction, The American Journal of Medicine, 134, 1085, 10.1016/j.amjmed.2021.03.014 · DOI · Paper page
- Sherratt, 2018, Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid, Biochemical and Biophysical Research Communications, 496
- Pisaniello, 2021, Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects, Atherosclerosis, 324, 27, 10.1016/j.atherosclerosis.2021.03.003 · DOI
- Libby, 2020, COVID-19 is, in the end, an endothelial disease, European Heart Journal, 41, 3038, 10.1093/eurheartj/ehaa623 · DOI · Paper page
- Teuwen, 2020, COVD-19: the vasculature unleashed, Nature Reviews Immunology, 20, 389, 10.1038/s41577-020-0343-0 · DOI · Paper page
- Kurahara, 2020, Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn, Journal of Molecular and Cellular Cardiology, 148, 50, 10.1016/j.yjmcc.2020.08.013 · DOI
- Liu, 2014, Eicosapentaenoic acid attenuates cigarette smoke-induced lung inflammation by inhibiting ROS-sensitive inflammatory signaling, Frontiers in Physiology, 5, 10.3389/fphys.2014.00440 · DOI
- Lemoine, 2020, Relationship between Omega-3 and Omega-6 Fatty Acid Intake and Chronic Obstructive Pulmonary Disease Morbidity, Annals of the American Thoracic Society, 17, 378, 10.1513/AnnalsATS.201910-740RL · DOI
Cited by
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688
Dinu, M., Sofi, F., Lotti, S., Colombini, B., Mattioli, A. V., Catapano, A. L., Casula, M., Baragetti, A., Wong, N. D., Steg, P. G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae184 · Cited by 43
Metadata
- Authors
- Sherratt, S. C. R., Libby, P., Bhatt, D. L., & Mason, R. P.
- Venue
- Prostaglandins, Leukotrienes and Essential Fatty Acids
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 182
- Pages
- 102450
- ISSN
- 0952-3278
- Cited by
- 43
- References
- 46
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.